Tysabri (natalizumab)
By Business Review Editor
Pharma Deals Review: Vol 2005 Issue 56 (Table of Contents)
Published: 5 Feb-2005
DOI: 10.3833/pdr.v2005.i56.719 ISSN: 1756-7874
Section: Deal Trackers
Fulltext:
Abstract
Tysabri belongs to a new class of humanised monoclonal antibody, known as selective adhesion molecule (SAM) inhibitors, that block α4β1-integrin mediated leucocyte migration into infl amed tissue...
This page is available to subscribers only.
Not a subscriber? Join here
Already Registered? Please login using the top left purple box.
Copyright: © IQVIA 2018